Autopsy report · NCT01239108

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

“The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to continue clinical development of this molecule.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Astex Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Relapsed/Refractory Leukemias

Interventions

SGI-1776

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Study of XL999 in Patients With Metastatic Colorectal Cancer
  “Study was terminated due to cardiac toxicities in the subjects” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.